This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–81. doi: 10.1053/j.seminoncol.2016.11.004.KazandjianDMultiple myeloma epidemiology and survival: a unique malignancySemin Oncol20164366768110.1053/j.seminoncol.2016.11.004528369528061985Open DOISearch in Google Scholar
Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(8):981–1114. doi: 10.1002/ajh.25117.RajkumarSVMultiple myeloma: 2018 update on diagnosis, risk-stratification, and managementAm J Hematol2018938981111410.1002/ajh.25117622312830400719Open DOISearch in Google Scholar
Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncology. 2018;4(9):1221–7. doi: 10.1001/jamaoncol.2018.2128.CowanAJAllenCBaracABasaleemHBensenorICuradoMPGlobal burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016JAMA Oncology2018491221710.1001/jamaoncol.2018.2128614302129800065Open DOISearch in Google Scholar
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87. doi: 10.1016/j.ejca.2018.07.005.FerlayJColombetMSoerjomataramIDybaTRandiGBettioMCancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018Eur J Cancer20181033568710.1016/j.ejca.2018.07.00530100160Open DOISearch in Google Scholar
Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011;25(4):689–96. doi: 10.1038/leu.2010.313.KapoorPRajkumarSVDispenzieriAGertzMALacyMQDingliDMelphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysisLeukemia20112546899610.1038/leu.2010.31321233832Open DOISearch in Google Scholar
Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259–66. doi: 10.1200/jco.2009.26.0638.MateosMVRichardsonPGSchlagRKhuagevaNKDimopoulosMAShpilbergOBortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trialJ Clin Oncol2010281322596610.1200/jco.2009.26.063820368561Open DOISearch in Google Scholar
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–69. doi: 10.1056/NEJMoa1112704.PalumboAHajekRDelforgeMKropffMPetrucciMTCatalanoJContinuous lenalidomide treatment for newly diagnosed multiple myelomaN Engl J Med20123661917596910.1056/NEJMoa111270422571200Open DOISearch in Google Scholar
Gaultney JG, Uyl-de Groot CA. Efficient allocation of novel agents in multiple myeloma: a work in progress. Oncologist. 2013;18(1):5–7. doi: 10.1634/theoncologist.2012-0484.GaultneyJGUyl-de GrootCAEfficient allocation of novel agents in multiple myeloma: a work in progressOncologist20131815710.1634/theoncologist.2012-0484355625623299778Open DOISearch in Google Scholar
Jakovljević M. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Economics Health economics and therapeutic pathways. 2014;15(1):27–32. doi: 10.7175/fe.v15i1.909.JakovljevićMOncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan marketEconomics Health economics and therapeutic pathways2014151273210.7175/fe.v15i1.909Open DOISearch in Google Scholar
Jakovljevic MB, Jovanovic M, Lazic Z, Jakovljevic V, Djukic A, Velickovic R, et al. Current efforts and proposals to reduce healthcare costs in Serbia. Serb J Experiment Clin Res. 2011;12(4):161–3. doi: 10.5937/sjecr1104161J.JakovljevicMBJovanovicMLazicZJakovljevicVDjukicAVelickovicRCurrent efforts and proposals to reduce healthcare costs in SerbiaSerb J Experiment Clin Res2011124161310.5937/sjecr1104161JOpen DOISearch in Google Scholar
Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Economics. 2003;4(3):143–50.SiebertUWhen should decision-analytic modeling be used in the economic evaluation of health care?Eur J Health Economics2003431435010.1007/s10198-003-0205-2Search in Google Scholar
Rochau U, Vukićević Đ, Angerer S, Schaffner M, Qerimi V, Conrads-Frank A, et al. Cost-effectiveness analysis on sequential treatment regimens for elderly patients with multiple myeloma. In: 11th DGGÖ Jahrestagung. Augsburg, 2019.RochauUVukićevićĐAngererSSchaffnerMQerimiVConrads-FrankACost-effectiveness analysis on sequential treatment regimens for elderly patients with multiple myelomaIn: 11th DGGÖ Jahrestagung. Augsburg,2019Search in Google Scholar
Siebert U. Using decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German health care system. GMS Health Technol Assess. 2005;1:Doc03.SiebertUUsing decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German health care systemGMS Health Technol Assess20051Doc03.Search in Google Scholar
Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making. 2012;32(5):690–700. doi: 10.1177/0272989x12455463.SiebertUAlagozOBayoumiAMJahnBOwensDKCohenDJState-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3Med Decis Making201232569070010.1177/0272989x12455463Open DOISearch in Google Scholar
Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667–77. doi: 10.1177/0272989x12454577.CaroJJBriggsAHSiebertUKuntzKMModeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1Med Decis Making20123256677710.1177/0272989x12454577Open DOISearch in Google Scholar
Novaković T, Tešić D, Stefanović D, Medić G, Sovtić D. Vodič za farmakoekonomske evaluacije. Belgrade: Savez farmaceutskih udruženja Srbije, 2011.NovakovićTTešićDStefanovićDMedićGSovtićDVodič za farmakoekonomske evaluacijeBelgradeSavez farmaceutskih udruženja Srbije2011Search in Google Scholar
Smith DH, Gravelle H. The practice of discounting in economic evaluations of healthcare interventions. Int J Technol Assess Health Care. 2001;17(2):236–43.SmithDHGravelleHThe practice of discounting in economic evaluations of healthcare interventionsInt J Technol Assess Health Care20011722364310.1017/S026646230010509411446135Search in Google Scholar
Serbian Myeloma Group. Multipli mijelom - dijagnostički i terapijski vodič. Accessed March 10th, 2019 at: http://smg.rs/download/SMG_vodic_2015.pdf.Serbian Myeloma GroupMultipli mijelom - dijagnostički i terapijski vodičAccessed March 10th, 2019 at: http://smg.rs/download/SMG_vodic_2015.pdf.Search in Google Scholar
Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112(8):3107–14. doi: 10.1182/blood-2008-04-149427.PalumboABringhenSLiberatiAMCaravitaTFalconeACalleaVOral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trialBlood2008112831071410.1182/blood-2008-04-14942718505783Open DOISearch in Google Scholar
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138(3):330–7. doi: 10.1111/j.1365-2141.2007.06656.x.KropffMBispingGSchuckELiebischPLangNHentrichMBortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaBr J Haematol20071383330710.1111/j.1365-2141.2007.06656.x17614819Open DOISearch in Google Scholar
Hjorth M, Hjertner O, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, et al. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012;88(6):485–96. doi: 10.1111/j.1600-0609.2012.01775.x.HjorthMHjertnerOKnudsenLMGulbrandsenNHolmbergEPedersenPTThalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyEur J Haematol20128864859610.1111/j.1600-0609.2012.01775.x349284422404182Open DOISearch in Google Scholar
Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009;82(6):426–32. doi: 10.1111/j.1600-0609.2009.01257.x.StadtmauerEAWeberDMNiesvizkyRBelchAPrinceMHSan MiguelJFLenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myelomaEur J Haematol20098264263210.1111/j.1600-0609.2009.01257.x270492519302559Open DOISearch in Google Scholar
Ponisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol. 2008;143(2):191–200. doi: 10.1111/j.1365-2141.2008.07076.x.PonischWRozanskiMGoldschmidtHHoffmannFABoldtTSchwarzerACombined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trialBr J Haematol2008143219120010.1111/j.1365-2141.2008.07076.x18752593Open DOISearch in Google Scholar
Hajek R, Masszi T, Petrucci MT, Palumbo A, Rosinol L, Nagler A, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017;31(1):107–14. doi: 10.1038/leu.2016.176.HajekRMassziTPetrucciMTPalumboARosinolLNaglerAA randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)Leukemia20173111071410.1038/leu.2016.176522012627416912Open DOISearch in Google Scholar
de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med. 2001;59(2):50–6.de WeerdtOvan de DonkNWVethGBloemACHagenbeekALokhorstHMContinuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myelomaNeth J Med200159250610.1016/S0300-2977(01)00140-1Search in Google Scholar
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17. doi: 10.1056/NEJMoa0801479.San MiguelJFSchlagRKhuagevaNKDimopoulosMAShpilbergOKropffMBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med200835999061710.1056/NEJMoa0801479Open DOISearch in Google Scholar
Dmoszynska A, Walter-Croneck A, Hus I, Grzasko N, Manko J, Jedrzejczak WW, et al. The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group. Leuk Res. 2010;34(10):1330–5. doi: 10.1016/j.leukres.2010.05.003.DmoszynskaAWalter-CroneckAHusIGrzaskoNMankoJJedrzejczakWWThe efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study GroupLeuk Res201034101330510.1016/j.leukres.2010.05.003Open DOISearch in Google Scholar
Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118(5):1231–8. doi: 10.1182/blood-2011-02-338665.MorganGJDaviesFEGregoryWMRussellNHBellSESzubertAJCyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationBlood201111851231810.1182/blood-2011-02-338665Open DOISearch in Google Scholar
Petrucci MT, Levi A, Bringhen S, Scotti S, Gentilini F, Russo S, et al. Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study. Cancer. 2013;119(5):971–7. doi: 10.1002/cncr.27820.PetrucciMTLeviABringhenSScottiSGentiliniFRussoSBortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 studyCancer20131195971710.1002/cncr.27820Open DOISearch in Google Scholar
Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79(7):867–74. doi: 10.1016/s0025-6196(11)62152-6.KumarSKTherneauTMGertzMALacyMQDispenzieriARajkumarSVClinical course of patients with relapsed multiple myelomaMayo Clin Proc20047978677410.1016/s0025-6196(11)62152-6Open DOISearch in Google Scholar
Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol. 2006;76(4):273–7. doi: 10.1111/j.1600-0609.2005.00610.x.PalumboAAvontoIBrunoBAmbrosiniMTBringhenSCavalloFIntravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myelomaEur J Haematol2006764273710.1111/j.1600-0609.2005.00610.x16519697Open DOISearch in Google Scholar
Ponisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132(4):205–12. doi: 10.1007/s00432-005-0074-4.PonischWMitrouPSMerkleKHeroldMAssmannMWilhelmGTreatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)J Cancer Res Clin Oncol200613242051210.1007/s00432-005-0074-416402269Open DOISearch in Google Scholar
Park S, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, et al. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. Ann Hematol. 2014;93(1):99–105. doi: 10.1007/s00277-013-1952-5.ParkSLeeSJJungCWJangJHKimSJKimWSDCEP for relapsed or refractory multiple myeloma after therapy with novel agentsAnn Hematol20149319910510.1007/s00277-013-1952-524240976Open DOISearch in Google Scholar
Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J Buon. 2007;12(1):41–4.DadacaridouMPapanicolaouXMaltesasDMegalakakiCPatosPPanteliKDexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patientsJ Buon2007121414Search in Google Scholar
Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol. 2013;161(6):802–10. doi: 10.1111/bjh.12325.GerrieASMikhaelJRChengLJiangHKukretiVPanzarellaTD(T)PACE as salvage therapy for aggressive or refractory multiple myelomaBr J Haematol201316168021010.1111/bjh.1232523594335Open DOISearch in Google Scholar
Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003;21(14):2732–9. doi: 10.1200/jco.2003.01.055.LeeCKBarlogieBMunshiNZangariMFassasAJacobsonJDTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myelomaJ Clin Oncol200321142732910.1200/jco.2003.01.055Open DOISearch in Google Scholar
Life table, Serbia. Accessed February 15, 2019 at: http://ec.europa.eu/eurostat/data/database.Life table, SerbiaAccessed February 15, 2019 at: http://ec.europa.eu/eurostat/data/database.Search in Google Scholar
Buchberger M, Rochau U, Vukićević Đ, Willenbacher W, Siebert U. Treatment strategies for elderly patients with newly diagnosed multiple myeloma: a meta-analysis and indirect treatment comparison. Value Health. 2015;18(7):A432. doi: 10.1016/j.jval.2015.09.1031.BuchbergerMRochauUVukićevićĐWillenbacherWSiebertUTreatment strategies for elderly patients with newly diagnosed multiple myeloma: a meta-analysis and indirect treatment comparisonValue Health2015187A43210.1016/j.jval.2015.09.1031Open DOISearch in Google Scholar
Vukićević Đ, Rochau U, Savić A, Buchberger M, Sroczynski G, Siebert U. Costs of sequential multiple myeloma treatment for elderly transplant-ineligible patients in the Serbian health care system. Med Pregled. 2019;72(3–4):88–97. doi: https://doi.org/10.2298/MPNS1904088V.VukićevićĐRochauUSavićABuchbergerMSroczynskiGSiebertUCosts of sequential multiple myeloma treatment for elderly transplant-ineligible patients in the Serbian health care systemMed Pregled2019723–48897https://doi.org/10.2298/MPNS1904088V10.2298/MPNS1904088VSearch in Google Scholar
National Health Insurance Fund. Rulebook of the reimbursed medicines. Accessed January 13, 2017 at: http://www.rfzo.rs/index.php/osiguranalica/lekovi-info/lekovi-actual.National Health Insurance FundRulebook of the reimbursed medicinesAccessed January 13, 2017 at: http://www.rfzo.rs/index.php/osiguranalica/lekovi-info/lekovi-actual.Search in Google Scholar
National Health Insurance Fund. Rulebook on prices of laboratory health services. Accessed January 13, 2017 at: http://www.rfzo.rs/download/pravilnici/ugovaranje/Pravilnik%20o%20cenama%20zdravstvenih%20usluga%20na%20sekundarnom%20i%20tercijarnom%20nivou%20zz-14112014.pdf.National Health Insurance FundRulebook on prices of laboratory health servicesAccessed January 13, 2017 at: http://www.rfzo.rs/download/pravilnici/ugovaranje/Pravilnik%20o%20cenama%20zdravstvenih%20usluga%20na%20sekundarnom%20i%20tercijarnom%20nivou%20zz-14112014.pdf.Search in Google Scholar
National Health Insurance Fund. Rulebook on prices of health services in secondary and tertiary health care. Accessed January 13, 2017 at: http://www.rfzo.rs/download/pravilnici/ugovaranje/Pravilnik%20o%20cenama%20zdravstvenih%20usluga%20na%20sekundarnom%20i%20tercijarnom%20nivou%20zz-14112014.pdfNational Health Insurance FundRulebook on prices of health services in secondary and tertiary health careAccessed January 13, 2017 at: http://www.rfzo.rs/download/pravilnici/ugovaranje/Pravilnik%20o%20cenama%20zdravstvenih%20usluga%20na%20sekundarnom%20i%20tercijarnom%20nivou%20zz-14112014.pdfSearch in Google Scholar
Purchasing power parities and related economic indicators. Accessed February 15, 2019 at: http://ec.europa.eu/eurostat/web/purchasing-power-parities/data/database.Purchasing power parities and related economic indicatorsAccessed February 15, 2019 at: http://ec.europa.eu/eurostat/web/purchasing-power-parities/data/database.Search in Google Scholar
Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. PharmacoEconomics. 2018;36(7):745–58. doi: 10.1007/s40273-018-0672-z.AttemaAEBrouwerWBFClaxtonKDiscounting in economic evaluationsPharmacoEconomics20183677455810.1007/s40273-018-0672-z599912429779120Open DOISearch in Google Scholar
Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012;32(5):733–43. doi: 10.1177/0272989x12454579.EddyDMHollingworthWCaroJJTsevatJMcDonaldKMWongJBModel transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7Med Decis Making20123257334310.1177/0272989x1245457922990088Open DOISearch in Google Scholar
Chhatwal J, Mathisen M, Kantarjian H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer. 2015;121(19):3372–9. doi: 10.1002/cncr.29512.ChhatwalJMathisenMKantarjianHAre high drug prices for hematologic malignancies justified? A critical analysisCancer2015121193372910.1002/cncr.2951226102457Open DOISearch in Google Scholar
Chen W, Yang Y, Chen Y, Du F, Zhan H. Cost-effectiveness of bortezomib for multiple myeloma: a systematic review. Clinicoecon Outcomes Res. 2016;8:137–51. doi: 10.2147/ceor.s104195.ChenWYangYChenYDuFZhanHCost-effectiveness of bortezomib for multiple myeloma: a systematic reviewClinicoecon Outcomes Res201681375110.2147/ceor.s104195Open DOISearch in Google Scholar
Blommestein HM, Verelst SG, de Groot S, Huijgens PC, Sonneveld P, Uyl-de Groot CA. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. Eur J Haematol. 2016;96(2):198–208. doi: 10.1111/ejh.12571.BlommesteinHMVerelstSGde GrootSHuijgensPCSonneveldPUyl-de GrootCAA cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease modelEur J Haematol201696219820810.1111/ejh.1257125892333Open DOISearch in Google Scholar
Garrison LP, Jr., Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, et al. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist. 2013;18(1):27–36. doi: 10.1634/theoncologist.2011-0380.GarrisonLPJr.WangSTHuangHBa-ManciniAShiHChenKThe cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatmentOncologist2013181273610.1634/theoncologist.2011-0380355625223299777Open DOISearch in Google Scholar
Guglielmelli T, Bringhen S, Rrodhe S, Gay F, Cavallo F, Berruti A, et al. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. Eur J Cancer. 2011;47(6):814–8. doi: 10.1016/j.ejca.2010.12.026.GuglielmelliTBringhenSRrodheSGayFCavalloFBerrutiAPrevious thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patientsEur J Cancer2011476814810.1016/j.ejca.2010.12.02621334196Open DOISearch in Google Scholar
Green T, Bron D, Chomienne C, de Wit TD, de Haas F, Engert A, et al. Costs of haematological disease high and rising. Lancet Haematol. 2016;3(8):e353–4. doi: 10.1016/s2352-3026(16)30074-6.GreenTBronDChomienneCde WitTDde HaasFEngertACosts of haematological disease high and risingLancet Haematol201638e353410.1016/s2352-3026(16)30074-6Open DOISearch in Google Scholar
Jakovljević MB, Đorđević N, Jurišević M, Janković S. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):521–30. doi: 10.1586/14737167.2015.1003044.JakovljevićMBĐorđevićNJuriševićMJankovićSEvolution of the Serbian pharmaceutical market alongside socioeconomic transitionExpert Rev Pharmacoecon Outcomes Res20151535213010.1586/14737167.2015.100304425592856Open DOISearch in Google Scholar
Radovanovic A, Dagovic A, Jakovljević M. Economics of cancer related medical care: estimates worldwide and available domestic evidence. Accessed November 27, 2019 at: https://ssrn.com/abstract=2376348.RadovanovicADagovicAJakovljevićMEconomics of cancer related medical care: estimates worldwide and available domestic evidenceAccessed November 27, 2019 at: https://ssrn.com/abstract=2376348.Search in Google Scholar
